Why the vascular category is structurally underbuilt
Cardiovascular disease accounts for 31% of global deaths annually, with 80%+ from coronary heart disease and stroke. Sub-Saharan Africa carries that burden younger — working-age populations bear more of the mortality than in high-income countries, attributable to under-prevention and incomplete access. South African national prevalence figures from systematic review (Keates et al., PMC 8756070): coronary heart disease 1.29 per 100 (95% CI 0.83-1.75), stroke 4.29 per 100 (95% CI 3.13-5.45). Cardiometabolic multi-morbidity — two or more of hypertension, diabetes, stroke or angina — affects 10.5% of South African adults; in the over-75 group, the adjusted odds ratio versus 15-29 year olds is 49.54 (95% CI 19.25-127.50).
The longevity industry's product mix does not reflect this burden. NMN, NR, urolithin A, senolytics, GLP-1 adjuncts and metabolic-focused stacks dominate brand launches in SEA and SSA. Vascular tone, endothelial function, venous insufficiency, claudication — the adjacencies that affect aging urban professionals daily — receive a fraction of the brand attention.
The clinical evidence base for vascular adjuncts
Pycnogenol (French maritime pine bark extract, standardised 70±5% procyanidins) has the strongest published evidence among vascular phytochemicals. The Cesarone et al. 2006 controlled study (Clin Appl Thromb Hemost. 2006 Apr;12(2):205-12, PMID 16708123) enrolled 86 patients with severe chronic venous insufficiency on either oral Pycnogenol 150 mg or 300 mg daily or Daflon (diosmin/hesperidin) 1,000 mg/day for 8 weeks. The authors' conclusion: "this study confirms the fast clinical efficacy of Pycnogenol in patients with chronic venous insufficiency and venous microangiopathy and its superiority — considering the evaluated parameters — to the combination of diosmin and hesperidin." Pycnogenol's mechanism: incorporation into venous walls, improved nitric oxide-mediated arterial dilation, and reduced capillary filtration. Diosmin/hesperidin remains the prescribed pharmaceutical option for CVI and operates on similar phlebotonic pathways at higher dose.
Adjacent vascular adjuncts with reasonable evidence: aged garlic extract for arterial stiffness; nattokinase for fibrinolytic markers; beetroot/citrulline for nitric oxide pathways; omega-3 EPA/DHA at therapeutic doses (≥2 g/day combined) for cardiovascular event reduction. The category does not require a moonshot ingredient — it requires disciplined formulation against established mechanisms.
Where the SEA and SSA market opens
The Singapore urban professional cohort over 45 — long-haul flying, desk-bound, alcohol-exposed — presents with early venous insufficiency symptoms (leg heaviness, mild oedema, restless legs) without clinical diagnosis. Same pattern in Johannesburg, Cape Town, Bangkok and KL urban professional segments. Existing aesthetic and wellness clinics treat the cosmetic surface (sclerotherapy, EVLT) but the daily-supplement layer is underbuilt — unlike metabolic or skin categories, where dozens of brands compete.
Distribution implication: a disciplined vascular-health product (Pycnogenol-centred or diosmin/hesperidin-based) sold into aesthetic and longevity clinics in Singapore, Johannesburg and Bangkok faces less brand-on-brand competition than another NMN. The clinical evidence is older and stronger than the trendier longevity ingredients. The patient education work is heavier — vascular literacy is lower than metabolic literacy in our segment.